New drug combo aims to make stem cell transplants safer for blood cancer patients
NCT ID NCT03314974
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing a stem cell transplant from a donor for people with various blood cancers and bone marrow disorders. The transplant uses strong chemotherapy or radiation to wipe out the diseased marrow, then replaces it with healthy donor cells. A new combination of three drugs (cyclophosphamide, tacrolimus, and mycophenolate mofetil) is given after the transplant to prevent graft-versus-host disease, a serious complication where donor cells attack the patient's body. The study aims to see if this approach reduces chronic graft-versus-host disease while still controlling the cancer. About 300 participants up to age 60 are being enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hematopoietic stem cell transplant (bone marrow or blood stem cells from a donor) followed by cyclophosphamide, tacrolimus, and mycophenolate mofetil
What this could lead to
If successful, this approach could improve survival and reduce severe side effects for people with blood cancers needing a stem cell transplant.
What could go wrong
This is a mid-stage trial, so results are not yet proven. Risks include graft failure, serious infections, and graft-versus-host disease, which can be life-threatening.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Masonic Cancer Center at University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55337, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••